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Background 
Merkel Cell Carcinoma (MCC) is a rare neuroendocrine tumor that is associated with old age and immunosuppressive condition. It 
has two distinct subgroups differentiated with their Merkel Cell Polyomavirus (MCPyV) positivity/negativity. While both groups are 
considered aggressive, the Merkel cell Polyomavirus negative group has significantly worse prognosis. Traditionally MCC cases 
have been diagnosed based on their physiological appearance and immunohistochemical markers such as cytokeratin 20 and tumor 
transcription factor-1, which differentiate MCCs from small cell carcinomas. It still requires skilled personnel such as dermatologists 
and pathologists to identify MCCs. More precise and effective biomarkers are required to improve MCC diagnostics, to enhance 
patient survival and in the development of personalized medicine for MCC. 
 
Neurocan (NCAN) is a chondroitin sulphate proteoglycan that is found mainly in central nervous tissue in adults. The core protein of 
Neurocan is formed of 3 domains, G1 containing a single immunoglobulin domain, the glycosaminoglycan binding backbone and G3 
domain containing regulatory protein-like sequences and epidermal growth factor/lectin-like domains. It is produced mainly by reac-
tive astrocytes and its main function is to guide the growth of axons and to participate in the formation of neural extracellular matrix. 
Neurocan is linked to inhibition of axonal regeneration and glial scarring in case of neural injury. There are few mentions of Neurocan 
changes related to cancer outside of the central nervous system, however, there is clear evidence of chondroitin sulphate proteogly-
can involvement in tumor invasiveness and potentially promotion of malignant tumor phenotype. 
 
Aim of the study and experimental design 
This thesis is a part of a project studying novel biomarkers and therapeutic targets for MCC. The aim of the study was to identify a 
novel cancer specific gene (Neurocan) that would be either a potential biomarker or therapeutic target, and to set up the pipeline for 
further expanding the parent project.  
 
Neurocan was first identified from outlier gene detection methods applied to MCC sample series containing samples of 141 MCC 
patients. After this Neurocan expression levels were studied at protein level using immunohistochemistry for MCC sample series. 
NCAN expression levels in MCC cell lines were investigated at mRNA and protein level with qPCR and Western blotting respectively. 
Functional studies of Neurocan such as an effect on cell proliferation were performed with siRNA knockdown assays, and analyzed 




144 FFPE samples in TMA (tissue microarray) format were stained for Neurocan protein expression; 31 samples expressed NCAN 
at low level, 60 at intermediate level and 53 cases had high NCAN expression. The low NCAN expression correlated with poor MCC 
specific survival (5-year survival 44%) when compared to intermediate and high expression groups (5-year survival 73% and 65% 
respectively). Kaplan-Meier survival analysis also implicated a significant difference in survival between the groups, p-value 0.044. 
NCAN expression levels had a strong association with Merkel Cell Polyomavirus (MCPyV) status (Pearson Chi-square, p-value = 
0.006) with 83% of high NCAN expression cases being MCPyV positive, where as 55% of low NCAN expression cases were MCPyV 
negative. Cox proportional hazards model revealed that NCAN is unlikely to be an independent variable in patient survival. 
 
NCAN expression correlated with the MCPyV status of 9 tested MCC cell lines (Student’s t-test, p-value = 0.041). Protein level 
studies were inconclusive due to lack of specific antibodies and testing methods.  
 
4 cell lines were tested for NCAN functionality in cell cultures. siRNA knockdown of NCAN did not affect the survival of MCC cell 
lines, however, it had a reducing effect on Large T-antigen expression of the MCPyV positive cell lines. Likewise, siRNA knockdown 
of Large T-antigen reduced the expression of NCAN mRNA in MCPyV positive cell lines. No such interactions were found in the 
MCPyV negative cell lines. siRNA knockdown of sT-antigen significantly reduced the growth of MCPyV positive WaGa cell line 
(Student’s t-test, p-value = 0.01). NCAN and large T-antigen targeting siRNAs had only a minor growth reducing effect on WaGa cell 
lines, and MKL1 cell line saw only minor growth reduction with all of the different siRNA treatments. These were not statistically 
significant findings. Whether Neurocan expression is directly controlled by MCPyV T-antigens, or whether the regulation is due to a 
signaling cascade of sorts, is still unknown. 
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Merkel Cell Carcinoma (MCC) is a rare neuroendocrine tumor that is associated 
with old age and immunosuppressive condition. It has two distinct subgroups dif-
ferentiated with their Merkel Cell Polyomavirus (MCPyV) positivity/negativity. 
While both groups are considered aggressive, the Merkel cell Polyomavirus neg-
ative group has significantly worse prognosis. Traditionally MCC cases have 
been diagnosed based on their physiological appearance and immunohistochem-
ical markers such as cytokeratin 20 and tumor transcription factor-1, which differ-
entiate MCCs from small cell carcinomas. It still requires skilled personnel such 
as dermatologists and pathologists to identify MCCs. More precise and effective 
biomarkers are required to improve MCC diagnostics, to enhance patient survival 
and in the development of personalized medicine for MCC. 
 
Neurocan (NCAN) is a chondroitin sulphate proteoglycan that is found mainly in 
central nervous tissue in adults. The core protein of Neurocan is formed of 3 do-
mains, G1 containing a single immunoglobulin domain, the glycosaminoglycan 
binding backbone and G3 domain containing regulatory protein-like sequences 
and epidermal growth factor/lectin-like domains. It is produced mainly by reactive 
astrocytes and its main function is to guide the growth of axons and to participate 
in the formation of neural extracellular matrix. Neurocan is linked to inhibition of 
axonal regeneration and glial scarring in case of neural injury. There are few 
mentions of Neurocan changes related to cancer outside of the central nervous 
system, however, there is clear evidence of chondroitin sulphate proteoglycan 
involvement in tumor invasiveness and potentially promotion of malignant tumor 
phenotype. 
 
Aim of the study and experimental design 
This thesis is a part of a project studying novel biomarkers and therapeutic targets 
for MCC. The aim of the study was to identify a novel cancer specific gene (Neu-
rocan) that would be either a potential biomarker or therapeutic target, and to set 
up the pipeline for further expanding the parent project.  
 
Neurocan was first identified from outlier gene detection methods applied to MCC 
sample series containing samples of 141 MCC patients. After this Neurocan ex-
pression levels were studied at protein level using immunohistochemistry for 
MCC sample series. NCAN expression levels in MCC cell lines were investigated 
at mRNA and protein level with qPCR and Western blotting respectively. Func-
tional studies of Neurocan such as an effect on cell proliferation were performed 




144 FFPE samples in TMA (tissue microarray) format were stained for Neurocan 
protein expression; 31 samples expressed NCAN at low level, 60 at intermediate 
level and 53 cases had high NCAN expression. The low NCAN expression cor-




intermediate and high expression groups (5-year survival 73% and 65% respec-
tively). Kaplan-Meier survival analysis also implicated a significant difference in 
survival between the groups, p-value 0.044. NCAN expression levels had a 
strong association with Merkel Cell Polyomavirus (MCPyV) status (Pearson Chi-
square, p-value = 0.006) with 83% of high NCAN expression cases being MCPyV 
positive, where as 55% of low NCAN expression cases were MCPyV negative. 
Cox proportional hazards model revealed that NCAN is unlikely to be an inde-
pendent variable in patient survival. 
 
NCAN expression correlated with the MCPyV status of 9 tested MCC cell lines 
(Student’s t-test, p-value = 0.041). Protein level studies were inconclusive due to 
lack of specific antibodies and testing methods.  
 
4 cell lines were tested for NCAN functionality in cell cultures. siRNA knockdown 
of NCAN did not affect the survival of MCC cell lines, however, it had a reducing 
effect on Large T-antigen expression of the MCPyV positive cell lines. Likewise, 
siRNA knockdown of Large T-antigen reduced the expression of NCAN mRNA in 
MCPyV positive cell lines. No such interactions were found in the MCPyV nega-
tive cell lines. siRNA knockdown of sT-antigen significantly reduced the growth 
of MCPyV positive WaGa cell line (Student’s t-test, p-value = 0.01). NCAN and 
large T-antigen targeting siRNAs had only a minor growth reducing effect on 
WaGa cell lines, and MKL1 cell line saw only minor growth reduction with all of 
the different siRNA treatments. These were not statistically significant findings. 
Whether Neurocan expression is directly controlled by MCPyV T-antigens, or 






























Review of the literature 
 
Merkel Cell Carcinoma 
 
C. Toker first used “trabecular carcinoma of the skin” in 1972 to describe a ma-
lignant skin cancer found in five elderly patients (Toker 1972).  It showed neural 
crest origin and resembled Merkel cells when studied with electron microscopy 
six years later (Tang, Toker 1978). The original name was questioned and even-
tually the name Merkel cell carcinoma (MCC) prevailed. However, there is still 
controversy about the origin of MCC. In 2013 Axel zur Hausen et al. reported that 
majority of MCC cases express terminal deoxynucleotidyl transferase (TdT) and 
paired box gene 5 (PAX 5) which, when co-expressed, would indicate that the 
cell of origin for MCC has to be pro/pre- or pre-B cells (zur Hausen, Rennspiess 
et al. 2013). While this is true, there are multiple studies favoring the hypothesis 
that MCC has origin in stem cells. For example, there are multiple studies demon-
strating that MCCs could differentiate from squamous or sarcomatous tissues 
(Hwang, Alanen et al. 2008, Walsh 2001) and others suggest neural crest origin 





MCC is often described as a rare neuroendocrine skin cancer that is associated 
with old age and immunosuppressive conditions. Other exposing factors include 
ultraviolet radiation and Merkel Cell Polyomavirus (MCPyV), the latter of which is 
a major contributor in tumorigenesis of MCC (Feng, Shuda et al. 2008, Sihto, 
Kukko et al. 2009, Becker, Schrama et al. 2008). A staggering 97% of MCC pa-
tients in Finland and in the United States are over 50 years old with more than 
2/3 patients being over 70 years old at the time of diagnosis (Lemos, Storer et al. 
2010, Kukko, Böhling et al. 2012). The age-adjusted incidence rate of MCC varies 
heavily, and is clearly associated with the availability of sunlight throughout the 
year. This is demonstrated by the annual incidence rates of Finland (1.2 per mil-
lion) versus Australia (8.2 per million) and Detroit (0.22/100 000) versus Seattle 
(0.9/100 000). (Kukko, Böhling et al. 2012, Hodgson 2005, Girschik, Thorn et al. 
2011) 
 
In the National Cancer Data Base people with ethnical background were found to 
comprise of only 3,8% of all MCC patients, compared to the vast majority (96,2%) 
of people with Caucasian background (Lemos, Storer et al. 2010). In a Finnish 
study cohort men and women had similar MCC incidence rates (Kukko, Böhling 
et al. 2012), but in cohorts from United States and Australia, men had slightly 
higher incidence rate (61,3% and 65% males, respectively) (Girschik, Thorn et 
al. 2011, Lemos, Storer et al. 2010).  
 
Most of the MCC lesions are non-tender (88%) and expand rapidly on a 3 month 
scale (63%)(Heath, Jaimes et al. 2008). While the majority of MCCs are consid-




metastasized cancer at presentation, the cancer is often fast to spread. In a Finn-
ish study 38% of treated MCC cases with stage I or II cancer had a recurrence,  
out of which over a third (35%) had a recurrence with either a local or distant 
metastasis. The stage of the cancer  has a drastic effect on patient survival, with 
patients staged I or II (at presentation) having a 5-year survival rate of over 67%, 
compared to stage III (metastasized disease) cancers 5-year survival rate of 17%. 
The study used American Joint Committee on Cancer TNM (tumor size/nodal 
status/metastasis) staging system from 2009, which has since been updated, 
however, the stages have remained similar in the most recent version from 2019. 
(Kukko, Böhling et al. 2012, American Cancer Society 2019) 
 
Most of MCCs are located at the head and neck area or other UV exposed sites 
(70-90%). MCC patients have also been reported to have over 30-fold chance of 
having chronic lymphatic leukemia. (Heath, Jaimes et al. 2008) Other immuno-
suppression conditions such as HIV/AIDS have also been known to increase the 
risk of MCC. In 2002 Engels et al. reported that in a cohort of 309 365 patients 
from the United States, patients with AIDS had 13,4 times higher relative risk to 
develop MCC than general population. (Engels, Frisch et al. 2002) It is also 
known that therapeutic immunosuppression heightens the risk of MCC. Immuno-
suppressed MCC patients are also often younger than average MCC patients, 
with 49% of them being under 50 years old. (GOOPTU, WOOLLONS et al. 1997, 
Koljonen 2006) 
 
Treatment and outcome 
 
Surgical resection of the primary tumor is most often the first line therapy for 
MCC. A surgical margin of 2-3cm is suggested to achieve clear histologic mar-
gins, however, there is evidence that surgical margins of 1-2cm are enough and 
further expansion of the margins has no additional benefit to patient survival. Lo-
cal recurrence is common and, even in patients with wide excision margins, the 
rate of local recurrence is between 25-40%. (Kukko, Böhling et al. 2012, Tello, 
Coggshall et al. 2018)  
 
Second line in MCC therapy is radiation therapy (RT). Depending on the location 
of the tumor and the morbidity of surgery, radiation therapy can be used as a 
primary therapy option as well. A retrospective study by Bhatia et al. showed that 
hazard ratios for Stage I and II MCCs did not differ statistically between only sur-
gery and primary radiation therapy. However, as an adjuvant therapy, RT reduced 
the risk significantly. Another study proved that local and nodal relapse rates of 
MCC were also similar between resection and radiotherapy (8.2% vs 11 % local 
and 33% vs 21 % nodal relapse, respectively). The NCCN (National Comprehen-
sive Cancer Network) recommends radiation dosages between 50-66Gy, de-
pending on the status of the patient and the usage of radiotherapy in MCC treat-
ment (50 Gy as adjuvant therapy combined to surgery with negative margins vs 
66 Gy for primary therapy at a non-resectable location). Table 1 is an excerpt 
from Bhatia et al. visualizing their findings. (Bhatia, Storer et al. 2016, Harrington, 






Stage I(n = 3369) (1341 deaths) 
 
 
Stage II(n = 1474) (800 deaths) 
 
 
HR (95% CI) P* HR (95% CI) P* 
Surgery/radiation  
 Surgery only  1.0  –  1.0  –  
 Surgery + radiation  0.71 (0.64 to 0.80)  <.001  0.77 0.66 to 0.89)  <.001  
 Radiation only  0.92 (0.65 to 1.30)  .62  1.03 (0.73 to 1.46)  .85  
Table 1. Hazard ratios of different treatments for MCC. HR = hazard ratio, CI = confi-
dence interval. (Bhatia, Storer et al. 2016) 
 
Other adjuvant therapies for MCC include chemotherapy, which is used mainly in 
palliative treatment. While initial responses to traditional chemotherapy (i.e. cis-
platin and doxorubicin) are decent (53-76%), the effect is often short lived and 
cancer progression occurs within 3-8 months (Voog, Biron et al. 1999). Chemo-
therapies are also often poorly tolerated and cause adverse side effects such as 
skin toxicities for 63% of patients (Garneski, Nghiem 2007). And while modern 
immune therapies have proven effective in the treatment of some Merkel Cell 
Carcinomas, roughly 50% of Merkel Cell Carcinomas are resistant to these ther-
apies (Pembrolizumab: overall response rate 50%; Avelumab: overall response 
rate 33%). Furthermore, half of the patients who get initial response to immune 
therapies relapse and become resistant to the treatments eventually. (Miller, 
Church et al. 2018, Femia, Prinzi et al. 2018, Harms, Paul W., Harms et al. 2018) 
 
 
Merkel Cell Polyomavirus 
 
Merkel Cell Polyomavirus (MCPyV) is the fifth recognized human polyomavirus, 
out of the 13 human polyomaviruses known today (Calvignac-Spencer, Feltkamp 
et al. 2016, Feng, Shuda et al. 2008). It belongs to the polyomaviridae family of 
viruses, a group of non-enveloped viruses with icosahedral capsids. They are 
fairly small, only 40-45nm in diameter, and contain a circular double stranded 
DNA molecule of roughly 5kbp. Like other polyomaviruses, MCPyV genome con-
tains a unique origin of replication (ORI) from where transcription can start bidi-
rectionally. On one side the transcription of so called early genes leads to non-
capsid proteins, often referred as the T-antigens, more of which will be discussed 
later. Capsid proteins VP1,VP2 and VP3 are transcribed from the other direction. 
Although the core structure of MCPyV is similar to other human polyomaviruses, 
Feng et al. reported that the closest relative to MCPyV based on their initial cDNA 
sequencing was the African green monkey virus. Figure 1 visualizes the structure 
of MCPyV genome as described by Feng et al. (Feng, Shuda et al. 2008, Johne, 





Figure 1. Merkel Cell Polyomavirus (Feng, Shuda et al. 2008). 
 
The name Merkel Cell Polyomavirus stems from the fact that MCPyV was origi-
nally discovered by Feng et al. from cDNA sequences of MCC patient samples. 
They hypothesized that as MCC resembles Kaposi’s sarcoma, as both are over-
expressed in immunocompromised patients, it might have similar mechanisms of 
tumorigenesis behind it. And as Kaposi’s sarcoma has been found to associate 
with a herpesvirus infection (Chang, Cesarman et al. 1994), they decided to 
check whether MCC samples would contain any viral cDNA. Out of 10 MCC pa-
tient samples 8 proved to be positive for a yet unknown virus, where as only 8,5% 
of control tissues from various sites and 16% of normal skin samples from im-
munocompromised patients and non-MCC skin tumors contained detectable 
amounts of this virus. (Feng, Shuda et al. 2008) 
 
The T-antigens in MCPyV can be spliced into three different variants: the large 
T-antigen, the small T-antigen and 57kT antigen. These T-antigens are known to 
have oncogenic properties, as they target tumor suppressor proteins such as the 
retinoblastoma protein (Rb), p53 and protein phosphatase 2 a (PP2A). While T-
antigens are evident in all MCPyV positive MCCs, there are unique variations to 
them, especially in the case of LT. In a study by Shuda et al. 2008, 9 out of 9 
MCCs harbored unique LT truncating mutations, where as in control samples of 
non-MCC origin 0 out of 4 samples had a LT truncating mutation. This is thought 




cycle arrest, or tumor compromising immune response. (Feng, Shuda et al. 2008, 




Soon after its discovery in 2008, MCPyV proved to be a key player in MCC tu-
morigenesis. Approximately 70-80% of MCCs are considered to be derived from 
MCPyV and the rest are mostly UV-radiation induced MCCs. Harms et al. discov-
ered that in MCPyV negative MCCs, 85% of mutations are C>T transitions, a 
typical finding for UV-induced DNA damage (Harms, Paul William, Vats et al. 
2015). They also showed that MCPyV negative tumors have a higher mutational 
burden and multiple mutations in known tumor suppressor genes such as p53, 
RB, NOTCH1 and PRUNE2. This has been shown to render proteins like p53 
and RB non-functional in MCPyV negative MCCs, resulting in similar pathogenic 
mechanisms as in MCPyV positive MCCs (Sihto, Kukko et al. 2011). UV-radiation 
is also known to increase the small T-antigen levels in non-pathogenic MCPyV 
positive skin samples (Mogha, Fautrel et al. 2010). When combining these factors 
to the preferential localization of MCC to UV exposed sites, it is clear that UV-
radiation is one of the most crucial factors in MCC tumorigenesis. (Harms, Paul 
William, Vats et al. 2015, Mogha, Fautrel et al. 2010, Koljonen 2006) 
 
Other important factors in MCC tumorigenesis are the T-antigens in MCPyV pos-
itive MCCs. The large T-antigen and small T-antigen are studied frequently where 
as the 57kT-antigens functions are fairly unknown. The 57kT-antigen is known to 
contain a DnaJ binding domain, which in highly similar 17kT-antigen of simian 
virus 40 (SV40) promotes cell cycle progression and cell proliferation (Boyapati, 
Wilson et al. 2003). Both also contain a RB binding domain (LXCXE domain) 
which can inhibit p130 and p107 proteins and activate E2F-transcription factor, 
promoting tumor growth (Boyapati, Wilson et al. 2003, Stubdal, Zalvide et al. 
1997).  
 
sT-antigens are highly conserved among polyomaviruses, and are often de-
scribed to be involved in viral cell cycle and cell transformation (Khalili, Sariyer et 
al. 2008). While MCPyV sT-antigen has multiple functions in viral replication, two 
interactions stand out when tumorigenesis is considered. Firstly, MCPyV sT-an-
tigen is known to target the translation regulator protein 4E-BP1, a downstream 
component of the PI3K-Akt-mTOR pathway (Shuda, Kwun et al. 2011). 4E-BP1 
is primarily responsible for regulation of eIF4F translation initiating complex 
through its mRNA cap binding component eIF4E. This eIF4F complex has been 
shown to suppress tumorigenic activity when functioning normally, and the loss 







In addition to sT-antigens’ ability to directly bind to 4E-BP1 it can also affect the 
upstream elements of the same pathway. MCPyV sT-antigen contains two PP2A 
binding domains, leading to activation of Akt through PP2A inactivation. As a well-
known oncogenic pathway, the PI3K-Akt-mTOR has been well studied and 
shown to be a critical factor in viral carcinogenesis (Shuda, Kwun et al. 2011, 
Feng, Kwun et al. 2011, Shuda, Feng et al. 2008). 
 
Lastly, the LT-antigen of MCPyV is the key players behind MCPyV tumorigenesis. 
While both 57kT and sT-antigens can affect crucial cellular functions inde-
pendently as described previously, they are often merely supporting elements for 
the LT-antigen. The LT-antigen contains a DnaJ binding domain, two tumor sup-
pressor protein domains (p53 and RB), origin binding domain and ATPase and 
helicase domains, as well as zinc finger and leucine zipper motifs. (Shuda, Feng 
et al. 2008) However, the LT-antigen is often truncated, leading to inability of viral 
reproduction as a result of losing the origin binding and/or ATPase/helicase do-
mains, as well as reduced functionality due to loss of, for example, p53 binding 
domain (Borchert, Czech-Sioli et al. 2014).   
 
In MCC tumorigenesis, two LT-antigen domains stand out from the rest, the p53 
and RB binding domains. While p53 domain of MCPyV LT-antigen is often in-
complete or completely truncated, studies have shown that MCPyV LT-antigen 
can indirectly reduce p53 activity in cell lines (Borchert, Czech-Sioli et al. 2014). 
This can result in uncontrolled growth and lack of apoptosis in cells (Sullivan, 
Pipas 2002). As Figure 3 visualizes, p53 restricts cell cycle by causing G2 and 
G1 growth arrest through signaling cascade involving p21, and can cause bax-
mediated apoptosis, if a cell undergoes excess DNA damage (Sullivan, Pipas 
2002).  
 
Figure 2. sT inhibition of PI3K-Akt-mTOR pathway. Red arrows indicate inhibitory interaction and green arrows 





Figure 3. Inhibition of tumor suppressor pathways by T-antigens by Sullivan et al. (Sulli-
van, Pipas 2002) 
 
Another tumor suppressor protein, RB, often has a complete binding domain de-
spite of the LT-antigen truncations. Interestingly, truncated LT-antigens showed 
even greater affinity to RB compared to a full length LT-variant (Borchert, Czech-
Sioli et al. 2014). Many cancers exploit the RB-E2F interaction by either mutating 
the RB protein or by affecting the up-/downstream signaling of the RB. This 
causes E2F mediated transcription, leading to production of S-phase genes and 




Neurocan (NCAN) or CSPG3 is a nervous tissue specific proteoglycan thought 
to be important in cell-to-cell and cell-to-matrix interactions. It consists of a core 
protein and one or more glycosaminoglycan (GAG) sidechains. The gene coding 
for the Neurocan protein is located in chromosome 19 and spans over nearly 1Mb 
of 19p12-13.1. It consists of 15 exons forming an open reading frame that consist 
of 3963 base pairs or 1321 amino acids. The exons 3-6 are used to code for the 
N-terminal of Neurocan and exons 9-14 are used to code for the C-terminal. 
These regions show high homology with other members of the proteoglycan fam-
ily (50% and 72% respectively) as well as with different species (92% both). Ex-
ons 7 and 8 are used for the central portion and have no significant homologies 
with other proteoglycans nor species, with the exception of mouse and rat Neu-
rocan protein having 57% (exon 7) and 29% (exon 8) homology.  
 
The N-terminus (G1 domain) of Neurocan is comprised of a single immunoglobu-
lin domain followed by multiple tandem repeats, whereas the C-terminus (G3 do-
main) is comprised of one or two epidermal growth factor-like domains, a lectin-




GAG backbone, onto which one or more chondroitin sulphate glycosaminoglycan 
(CS-GAG) polysaccharides attach. While the primary structure is similar in prote-
oglycans, the central portions are unique to each proteoglycan. The size of pro-
teoglycan core proteins varies between 95 kDa to 400 kDa and the number of 
CS-GAGs can be anything between 1 and 100 units. (Prange, Pennacchio et al. 
1998, Lau, Cua et al. 2013) Figure 4 by Lau et al. visualizes the general structure 
of lecticans including Neurocan. 
 
Rauch et al (1995) reported that Neurocan protein concentrations are highest in 
neonatal rat brains comprising 20% of all chondroitin sulphate proteoglycans 
while in adult rats the amount is 6%. (Rauch, Grimpe et al. 1995) The protein is 
developmentally regulated in other fashions as well. For example, the molecular 
weight of rat fetus Neurocan protein is 245kDa, where as in 7-day-old rats the 
predominant form has a molecular weight of 150kDa. (Prange, Pennacchio et al. 





Figure 4. CSPG structure by Lau et al. (Lau, Cua et al. 2013) 
 
Functions of Neurocan protein 
 
The main function of NCAN protein is to guide axonal growth and to stabilize the 
extracellular matrix of central nervous system. While we are focused on Neu-




of these functions described hereafter. For the axonal growth guidance, two 
methods of action have been proposed by which this could happen. Method 1 is 
based on axon inhibition, where as method 2 relies on “addictive” growth of axons 
in CSPG rich areas. In method 1, CSPGs form a dense barrier around target 
areas and force the growing axons to divert from their path. (Silver, D. J., Silver 
2014) This sort of behavior has been shown to happen during development, for 
example, when CSPG barriers block axons from protruding through spinal cords 
roof plate (Snow, Steindler et al. 1990)  
 
This is also a form of protection during CNS injury. Reactive astrocytes have been 
shown to form a barrier around injured area or CNS lesions. This barrier consists 
not only from the reactive astrocytes themselves, but also of intermediate filament 
proteins and astrocyte produced CSPGs and KSPGs (keratin sulphate proteogly-
cans). The main purpose of these barriers is to isolate the injured area from 
healthy tissue to prevent the damage from spreading while also protecting the 
damaged area from excess inflammation causing unrecoverable cell damage. 
(Silver, J., Miller 2004) 
 
The second method involves CSPG preferential receptors on, for example, mi-
grating neuroblasts and extending axons. Neurons grown together with Schwann 
cells expressing CSPGs tend to grow axons along the Schwann cells, but when 
the CSPG expression is diminished or the CS-GAG chains of the CSPGs are 
degraded, the growth patterns change. The axons can completely abandon the 
Schwann cells, and can start infiltrating surrounding cells/tissues (Silver, D. J., 
Silver 2014, Grimpe, Pressman et al. 2005, Kuffler, Sosa et al. 2009). Interest-
ingly, even though the axons seem to prefer the Schwann cells when expressing 
CSPGs, the growth of the axons can multiply by up to 11-fold when treated with 
Chondroitinase-ABC, which cleaves the N-acetyl glucosamine and glucouronic 






Figure 5. Axonal guidance by CSPGs by Silver et al. a) represents the inhibitory turning 
pattern of CSPG mediated axonal growth (method 1) where as b) represents the “addic-
tive” growth pattern, method 2. (Silver, D. J., Silver 2014) 
 
This can also backfire, as is case in glial scarring. Axonal regrowth is hindered 
by entrapment of axons by neural glia expressing NG2 (CS-GAG receptor), and 
this can cause permanent stall in the axonal growth. Studies have shown that 
these “traps” can be disarmed by cleaving the CS-GAGs from CSPGs with Chon-
droitinase-ABC, resulting in renewed axonal growth. However, this can be trou-
blesome, since the presumed purpose of this sort of behavior and glial scarring, 
is to repair the severed blood-brain barrier and to limit the inflammatory re-
sponses in the area (Silver, J., Miller 2004). There is also evidence that cleavage 
of the CSPGs are behind invasive type brain tumors such as invasive glioma and 
invasive low-grade astrocytoma (Zhang, Kelly et al. 1998, Varga, Imre, Hutóczki 





The other important function of Neurocan is to form perineural nets found in the 
ECM. CSPGs form one of the three major components of CNS ECM by attaching 
to hyaluronan and tenascin-R with their G1 and G3 domains respectively. (Silver, 
D. J., Silver 2014). These structures can further attach to laminin, fibronectin, 
collagen and even cell bodies of neurons and glial cells, forming a dense net in 
the CNS. During embryonal development proliferation, migration and forming of 
synapses (synaptogenesis) are possible due to the loose ECM structure in the 
CNS. This all changes in postnatal development, as ECM molecules such as 
CSPGs start forming perineural nets, surrounding synapses and bringing ECM 
molecules tighter together. This limits the plasticity of the CNS, enabling proper 
synaptic function for example. (McRae, Porter 2012, Lau, Cua et al. 2013, Silver, 
D. J., Silver 2014) Figure 6 visualizes these perineural nets as depicted by Lau 
et al. 2013.  
 
 
Figure 6. Extracellular matrix molecules and the perineural nets of CNS by Lau e al. (Lau, 
Cua et al. 2013) 
 
Neurocan and cancer 
 
While there are only a few studies directed towards NCAN in cancer, proteins 
from the same CSPG family (Brevican and Versican) have been studied and can 
shed light into NCANs potential tumorigenic properties. Studies of NCAN in can-
cer are mostly related to cancers with neural crest origin, and only one study to 
our knowledge has highlighted the potential association of NCAN with cancer as 
a single nucleotide polymorphism in NCAN gene associated with higher risk of 
hepatocellular carcinoma in a study by Nischalke et al. The NCAN rs2228603 
polymorphism proved to be significantly more frequent in alcoholic liver disease 




alcoholic and alcoholic cirrhosis controls (7.2% and 9.3% respectively) and hep-
atitis C virus associated hepatocellular carcinoma (9.1%). (Nischalke, Lutz et al. 
2014) Whether this was a driving factor in the oncogenesis, or a collateral dam-
age remained uncertain. 
 
It is commonly known that tumors manipulate the surrounding cells and ECM to 
promote their growth and invasiveness (Henke, Nandigama et al. 2020). As 
NCAN is known to be responsible for the integrity of the ECM of CNS, as de-
scribed previously, it is no surprise that its potential in tumor infiltration has been 
studied frequently. For example, Varga et al. reported that Neurocan alongside 
with Brevican, Versican and Tenascin-C would be responsible for invasive phe-
notype in low-grade astrocytoma. They compared the mRNA expression levels 
of normal brains, astrocytoma, schwannoma and intracerebral non-small cell lung 
cancer (NSCLC), and found that the before mentioned four proteins separated 
the infiltrative semi-malignant astrocytoma from the benign schwannoma and 
poorly infiltrating NSCLC metastasis. (Varga, Imre, Hutóczki et al. 2012)  
 
In their earlier study, Varga et al. studied the invasion related ECM molecules in 
glioblastoma, and found that Tenascin-C, CD44 and MMP-2 were heavily in-
volved in the infiltration potential of glioblastoma. While NCAN was not found to 
be significantly different between glioblastoma and normal brain, it is noteworthy, 
that Tenascin-C, CD44 and NCAN are all related via perineural net formation, 
where as MMP-2 is known to degrade both NCAN and CD44. (Varga, I., Hutóczki 
et al. 2010, Yao, Tucker et al. 2011, Frischknecht, Seidenbecher 2008) As shown 
previously, perineural nets are crucial in the stability of the ECM of CNS, which 
when tampered with can be potentially beneficial for tumor infiltration.  
 
Another study illustrating the potential role of NCAN in metastasis focused on 
Brevican, a close relative of NCAN that shares many functions and is similar in 
structure to NCAN. (Silver, D. J., Silver 2014). Zhang et al. discovered that a 
cleaved Brevican protein induced tumor infiltration both in vitro and in vivo. Neo-
natal rat brains were implanted with otherwise non-invasive, non-Brevican ex-
pressing 9L glioma cell line, and transfected with either GFP (control), full length 
Brevican or a cleaved version of Brevican (Figure 7). In cell culture, cells treated 
with either full length or cleaved Brevican both showed increased invasiveness, 
but in rat xenografts, only cleaved Brevican showed increased cell infiltration. 






Figure 7. CSPG and tumor infiltration by Zhang et al. A (A') and B (B') tumors show little 
to no invasive cell clusters, where as C (C') tumor shows a lot of infiltrated cell clusters. 
A) 9L glioma cell line, intracranial injection. B) 9L cell line transfected with full form (func-
tional) BEHAB/Brevican. C) 9L cell line transfected with HABD, a cleaved N-terminal 
version of Brevican. (Zhang, Kelly et al. 1998) 
 
 
Stromal Versican (a member of the lecticans like Brevican and Neurocan) has 
been shown to associate with cancer inhibition through cancer-associated fibro-
blasts. Depletion of VCAN in mice xenografts showed decreased number of can-
cer-associated fibroblasts, resulting in thinner stromal barriers and unclear 
boundary around tumors. (Fanhchaksai, Okada et al. 2016) As described previ-
ously, one of the major functions of Neurocan and other CSPGs is isolation of 
injured areas by formation of barrier-like structures. As cancers often resemble 
lesions and other injuries (depending on its location), it is not surprising that the 
first reaction to this lesion like injury would be to treat them as lesions. So, barrier 
formation such as this could be one of the explaining factors to how CSPGs are 
linked to cancer invasiveness. Indeed, Silver et al. demonstrated that tumor infil-
tration of high-grade gliomas occurs in areas where CS-GAG-rich matrix is re-
duced (Silver, D. J., Siebzehnrubl et al. 2013). And as Zhang et al. highlighted, a 
complete Brevican protein is required for efficient inhibition of tumor invasive-
ness. 
 
In a recent study, Su et al. discovered that high expression of NCAN is associated 
with poor prognosis in neuroblastoma. They also proved that exogenous NCAN 
could potentiate spheroidal growth of neuroblastoma cells, which is often associ-
ated with undifferentiated and malignant phenotype. The knockdown of NCAN 
resulted in growth reduction in vitro, and the mRNA levels of stem cell markers 
such as OCT4, Nestin and ABCG2 were reduced. (Su, Kishida et al. 2017) While 
these results may seem contradictory to the ones mentioned previously, it needs 




related (LAR) receptor family, Protein Tyrosine Phosphatase Receptor (PTPR) 
family, and Epidermal Growth Factor Receptor (EGFR) for instance (Shen, Ten-
ney et al. 2009, Lau, Cua et al. 2013). Some of these receptors are known to 
have cell transforming and oncogenic potential, so if CSPGs are overexpressed 




Aims of the study 
 
Identification of novel biomarkers and therapeutic targets for MCC 
 
Rare Cancers Research group has acquired a vast amount of MCC patient sam-
ples and data (gene expression levels, outlier genes etc.) relating to these sam-
ples. This project is the first step of a larger study aiming to discover potential 
biomarkers and therapeutic targets in Merkel Cell Carcinoma. In the beginning of 
this project, the patient sample data was scrutinized, and one gene of interest 
(Neurocan) was identified to serve as a model for the upcoming studies. 
 
 
Frequence and prognostic role of Neurocan expression in MCC 
 
Protein expression levels of Neurocan was investigated in the MCC sample se-
ries with immunohistochemistry. Primarily, we investigated whether Neurocan 
protein expression relates to the findings in RNA sequencing, and if MCPyV pos-
itive tumors clearly differ from MCPyV negative tumors. This will verify the func-
tionality of the bioinformatics pipeline, and support in the construction of a work-
ing biomarker identification pipeline for the parent project. Secondly, association 
between Neurocan protein expression and clinical features, such as cancer stage 
and patient survival was investigated, as this will be an indication of Neurocans’ 
potential as a biomarker in MCC diagnostics.  
 
 
Importance of neurocan in MCC tumorigenesis 
 
After verifying the bioinformatics findings in the MCC patient sample series, we 
investigate the Neurocan expression in our MCC cell lines. The expression levels 
were analyzed primarily with qPCR and secondarily with Western Blotting. Fur-
thermore, the role of Neurocan in MCC tumorigenesis was studied with methods 
of modern molecular biology. The studies included methods such as cell prolifer-
ation assays (cancer growth) and whether shutting down Neurocan with siRNA 







Materials and Methods 
 
MCC sample series 
 
The MCC sample series is a collection of Merkel Cell Carcinoma patient samples 
from the Finnish cancer registry. This collection is the biggest population based 
MCC series, and holds over 200 patient samples collected between years 1983-
2018. The collection has been gathered and is maintained in collaboration with 
Rare Cancers Research group and the Finnish Biobanks. Clinical features used 
in the project (such as patient survival, cancer stage and cancer location) were 
collected from the Finnish Cancer Registry.  
 
 
MCC cell lines 
 
10 Merkel Cell Carcinoma cell lines were used in this study, some of which were 
acquired from the European Collection of Authenticated Cell Cultures (ECACC), 
and others kindly provided by Dr. Roland Houben and Prof. Annamari Ranki. Out 
of these 10 cell lines 6 were Merkel Cell Polyomavirus positive: BroLi, MKL1, 
MKL2, MS1, PeTa and WaGa. The rest were Merkel Cell Polyomavirus negative: 
MCC13, MCC14/2, MCC26 and UISO. We also partly included a fifth polyoma-
virus negative cell line, ME212, which has been established recently in collabo-
ration with Prof. Leif Andersson.  
 
 
3’ RNA sequencing 
 
RNA for the sequencing was extracted from formalin-fixed paraffin embedded 
tissue (FFPE) blocks with QiaSymphony according to manufacturer’s protocols. 
Prior to extraction, two 10 µm sections were dissected from the paraffin blocks 
and paraffin from the sections was removed. This was achieved by incubating 
the sections in +56°C in Qiagen deparaffinization solution (Qiagen #939018). Af-
ter deparaffinization, proteinase K (Qiagen #19133) was added to inactivate en-
dogenous RNAses and to start the cell lysing. This was followed with an hour-
long incubation in +56°C on a shaker, and the following liquefied samples were 
then transferred into the QiaSymphony for processing. The RNA was then ex-
tracted with Qiagens ready-made protocol, “RNA_FFPE_130_V7 protocol”, 
which comes pre-installed in the QiaSymphony.  
 
The 3’ sequencing was performed in collaboration with FIMM. RNA libraries for 
sequencing were prepared with QuantSeq 3’ mRNA-Seq Library kit (Lexogen, 
Vienna, Cat.no.: 015.96) and sequenced using the NovaSeq 6000 instrument 
with with NovaSeq S1 XP NS1-200 protocol (Illumina Inc.) at the Institute of Mo-
lecular Medicine Finland (FIMM, Helsinki, Finland). Lexogen QuantSeq 3’ work-
flow is introduced in Figure 8. MediSapiens ltd. analyzed the sequencing data. 














Data analysis of MCC RNA sequencing data 
 
The data analysis (bioinformatics) of the sequencing data was performed in col-
laboration with MediSapiens ltd. The bioinformatics pipeline included SIBER 
analysis, Gene tissue indexing, Gene set enrichment analysis and IST ranking. 
These methods are described in other publications (Tong, Chen et al. 2013, 
Subramanian, Tamayo et al. 2005, Mpindi, Sara et al. 2011), except for IST rank-
ing, which is developed by MediSapiens ltd. and has yet to be made publicly 
available. The IST ranking working principle, shortly, is as follows: gene expres-
sion of differently expressed genes is analyzed with deseg2 and the differently 
expressed genes (DEGs) are ranked by their expression. The following DEGs 
are filtered with 1,5 fold expression cut-off per subtype. The following gene list is 
then compared with lists from the IST-online database (normal and cancerous), 
and if a gene was represented in the top 500 highest expressed genes of either 
list, it was removed. The remaining list should be comprised of highly expressed 





Tissue microarray samples (TMA) were prepared from patient samples and 
stained for Neurocan protein expression. The samples were first deprived of par-
affin with descending alcohol series followed by endogenous peroxidase blocking 
with H2O2. The samples were then washed twice with TBS (5 minutes in room 
temperature [RT’]) and heat-induced epitope retrieval (15 minutes in 95°C) was 
performed in EnVision™ Flex Target Retrieval solution Low pH buffer (Dako, REF 
K8005) with Biocare Medical Decloaking chamber. Two washes with TBS (5 min 
each) were administered and primary NCAN antibody (Atlas antibodies, 
HPA036814) was applied on the samples, diluted 1:1000 in Draco antibody dilu-
ent (WellMed, Cat.no.: AD500), and left to incubate overnight at +4°C. After two 
washes (TBS, 5 min each) horseradish peroxidase (HRP) conjugated secondary 
anti-Rabbit antibody (1 step detection system rabbit HRP [WellMed, Cat.no.: 
R500HRP]) was applied on the samples for one hour RT’ followed by another two 
washes (TBS, 5 min each). Finally, the samples were stained with ImmPACT 
DAB Substrate kit (Vector laboratories, REF SK4105) and counterstained with 
hematoxylin. The complete immunohistochemistry protocol used in this study can 
be found in Appendix 2. 
 
The stained TMAs were then digitalized in collaboration with Helsinki Biobank. 
The digitalized TMAs were analyzed for the intensity of their NCAN staining, cor-
relating with the protein expression levels of NCAN. The samples were then as-
signed into three groups based on their expression levels: low NCAN expression, 
intermediate NCAN expression and high NCAN expression. NCAN negative sam-
ples were not found in our dataset. Examples of the staining intensities are visu-
alized in Figure 9. The evaluation of the staining intensity was done blinded, 




at the time of analyzing the samples. The results were then combined with pa-
tients’ clinical data and analyzed as described later. 
 
 
Figure 9. Different NCAN protein expression levels as seen with immunohistochemistry. 
From left: low, intermediate and high NCAN expression. 
 
Other immunohistochemical markers used in the study, such as large T-antigen 
(CM2B4), Ki-67 and RB were stained prior to this study and have been described 





Normal cell lines were cultured on 6-well plates (Corning, Greiner bio-one, REF 
657160) until they reached ~70% confluence (preparation siRNA protein lysates 
described later). Protein lysates were extracted from the cells with Pierce™ RIPA 
buffer (Thermo Scientific, REF 89900) supplemented with 1x HALT™ Protease 
& Phosphatase Single-Use Inhibitor Cocktail (Thermo Scientific, REF 78442) 
containing 5mM EDTA (Thermo Scientific, Prod# 1860851). Protein concentra-
tions were analyzed with Pierce™ BCA Protein Assay Kit (Thermo Scientific, REF 
23227) using Hidex Sense for absorbance measurements. The lysates were then 
diluted 1:1 with 2x Laemmli Sample Buffer (Bio-Rad, Cat. #1610737) supple-
mented with 5% β-Mercaptoethanol and boiled for 10 minutes at 95°C to denature 
the proteins. Attachment 3 contains the entire western blotting procedure as is 
described here. 
 
Denatured proteins were then separated from each other with SDS-PAGE gel 
electrophoresis. The samples were pipetted on a Bio-Rad Mini-PROTEAN TGX 
gel (Bio-Rad, Cat#4561033) and the gel was placed on BIORAD Bio-Rad Mini 
Trans-blot cell. A constant voltage (100V) was applied for roughly 1,5 hours to 
separate proteins based on their molecular weight.  
 
The gel containing the proteins and a Trans-Blot Turbo Transfer Pack (Bio-Rad, 
Cat. #1704156) were stacked according to manufacturer’s instructions and the 
proteins were transferred onto a PVDF membrane (included in the transfer pack). 
Bio-Rad Trans-Blot Turbo Transfer System was used for the protein transfer, with 
a Bio-Rad predefined program (mixed molecular weight, constant 1,3A, 7 






Two washes (5 minutes at room temperature) with western blot wash buffer (later 
called WB, contains 0,1% Tween20 [Thermo Scientific, BP337-100] in TBS) were 
administered to the membrane prior to blocking non-specific binding of antibodies 
with the WB supplemented with 5% low-fat milk. The membrane was washed 
twice as mentioned previously before treating the membrane with primary anti-
body. For NCAN and MCPyV LT (CM2B4), antibodies from Atlas Antibodies 
(NCAN, HPA036814), Merck/Sigma Aldrich (NCAN, N0913) and Santa Cruz Bi-
otechnology Inc. (CM2B4, sc-136172) were used at 1:1000 dilution (1% milk in 
WB). Actin from Bethyl Laboratories (Bethyl Laboratories, A300-491A) was used 
at 1:100 000 dilution (1% milk in WB) as a housekeeping protein. All of the pri-
mary antibodies were incubated over night at +4°C on their own membranes.  
 
The membrane was washed twice as previously, and secondary antibody was 
applied for the membrane. For Atlas Antibodies NCAN, rabbit-anti-mouse IgG 
Jackson ImmunoResearch, REF 315-035-003) was applied at 1:10 000 dilution 
(1% milk in WB), and for Merck NCAN, CM2B4 and Actin, goat-anti-rabbit (Jack-
son ImmunoResearch, REF 111-035-003) was applied at 1:10 000 dilution (1% 
milk in WB). All of the secondary antibodies were incubated for 1 hour at room 
temperature. After this, the membrane was washed twice and a chemilumines-
cent substrate (SuperSignal West Pico PLUS [Thermo scientific, REF 34580]) 






RNA samples were extracted from normal and siRNA treated cell lines (described 
later) with NucleoSpin RNA (Macherey-Nagel, REF 740955.50) kit according to 
manufacturers’ protocols. DNA samples for LT gene copy number (MCPyV status 
verification) were extracted for another project beforehand (unpublished data). 
The quality and quantity of the RNA and DNA samples were then measured with 
NanoDrop 1000 (Thermo Fisher Scientific) spectrophotometer. 100ng of each 
RNAs were then used as template for cDNA synthesis, performed with iScript 
cDNA Synthesis kit (Bio-Rad, Cat. #1708891) according to the manufacturers 
protocol. The cDNA quantity and quality was measured with NanoDrop 1000.  
 
Large T-antigen (LT) gene copy number was studied with Universal ProbeLibrary 
based qPCR assay, using LightCycler 480 Probes Master kit (Roche diagnostics, 
REF 04887301001) and Universal ProbeLibrary Set (Roche diagnostics, REF 
04683633001) according to the manufacturers’ recommendations. This was done 
to verify the MCPyV status of our cell lines. Protein Tyrosine Phosphatase Re-
ceptor Type G (PTPRG) was used as a reference gene. LT and PTPRG primers 
were designed and are described in more detailed in an article from Sihto et al. 
(Sihto, Kukko et al. 2009), and briefly in the Appendix 1. Any positive qPCR re-
action was considered as a positive finding for MCPyV.  
 
The NCAN and LT mRNA expression levels were studied with SYBR Green (BIO-
RAD, SsoAdvanced Universal SYBR Green Supermix, cat no. 1725270) based 




designed with Universal ProbeLibrary Assay Design Center (Roche Diagnostics) 
and The GAPDH primers were designed for another project (unpublished data) 
with GETprime (https://gecftools.epfl.ch/getprime). The primers are described 
further in Appendix 1. 
 
Bio-Rad CFX96 (thermal cycler) and Bio-Rad CFX Maestro (software) were used 
for the qPCRs. For both of the methods (Universal ProbeLibrary and SYBR 
Green), a total of 100ng of DNA (MCPyV status) or cDNA template and a final 
concentration 0,5µM of both forward and reverse primers were used for each 
reaction. The complete protocols can be found in Appendix 4. 
 
 
NCAN knockdown with siRNA transfections 
 
Pre-designed ON-TARGETplus siRNAs from Horizon discovery (ON-TARGET-
plus Human NCAN siRNA, Catalog ID: L-019794-01-0005) were used to knock-
down Neurocan expression in 2 MCPyV+ MCC cell lines (WaGa and MKL1) and 
2 MCPyV- MCC cell lines (MCC13 and MCC26). Custom siRNAs targeting large 
T-antigen (5’-AAGAGAGGCTCTCTGCAAGCT-3’) and small T-antigen (5’-AAGTT-
GTCTCGCCAGCATTGT-3’) were designed in another publication, and provided 
by Horizon Discovery (Kwun, Guastafierro et al. 2009). ON-TARGETplus Non-
targeting Pool (Horizon discovery, D-001810-10-20) was used as a non-targeting 
control, and siGLO Green Transfection Indicator (Horizon discovery, D-001630-
01-05) was used to optimize the siRNA transfection conditions. Lipofectamine 
2000 and 3000 (Invitrogen, REF 11668-019 and REF L3000-015 respectively) 
transfection reagents were tested for optimal transfection capability, and Lipofec-
tamine 2000 was eventually used in the knockdown assays. 
 
For protein and RNA lysates 100 000 cells for MCC13 and MCC26, and 400 000 
cells for MKL1 and WaGa cell lines were plated on 6-well plates (Greiner bio-one, 
REF 657160). For cell proliferation assays 10 000 cells for MCC13 and MCC26, 
and 20 000 cells for MKL1 and WaGa cell lines were plated on a 96-well plate 
(Corning, 3596). For both experiments, cells were counted and plated in growth 
media on day 0. On day 1, cells were transfected  with siRNAs (final concentration 
75 nM) using 0,33 µl/well or 6 µl/well of Lipofectamine 2000 for 96-well plate and 
6-well plates respectively. First, a mixture of Lipofectamine 2000 and target (or 
control) siRNA was prepared in Opti-MEM (Gibco, REF 31985-047) and incu-
bated in room temperature for 5 minutes, as per manufacturers’ instructions. The 
following mixture was then applied to cells, and the cells were grown for 0-72 
hours, depending on the experiment. For protein and mRNA lysates, cells were 
grown for 72h where as for cell proliferation studies, 3 different time points were 
used: 0h, 48h and 72h. After the incubation, the lysates were prepared as de-
scribed previously, or the cell proliferation was measured as described next. 
 
 
Cell proliferation with CellTiter-GLO 
 
Cell proliferation was measured with CellTiter-GLO Luminiscent Cell Viability As-




reaction where luciferin is transformed into oxyluciferin. In the process, a lumi-
nescent signal will be produced. Since ATP is produced by living cells, the 
amount of luminescent light will correlate with the number of living cells in a sam-
ple.  
MCC cell lines were transfected with siRNAs as described previously. Trans-
fected cells were grown for three different time points: 0, 48 and 72 hours. After 
this, premade CellTiter-GLO reagent was added to the cells following the manu-
facturers’ instructions, and the luminescence was measured with Hidex Sense. 
Due to a mistake in the experimental setting, complete data is available only from 
MKL1 and WaGa cell lines. The MCC13 and MCC26 experiments were sched-
uled after the MCPyV positive cell lines, but due to the recent outbreak of COVID-





All statistics were analyzed with either IBM SPSS Statistics 25 or Rstudio version 
1.2.5033. Apart from the bioinformatics data that was provided by MediSapiens 




Identification of NCAN 
 
141 RNA samples were sequenced, out of which 111 (79%) had good enough 
quality to be processed further in the bioinformatics pipeline. The gene expres-
sion was derived from the samples with deseq2 and further on the outlier genes 
were detected from the deseq2 data with multiple different detection methods: 
SIBER, GTI, ranked gene list (deseq2 based, MCPyV+ vs MCPyV- cases) and 
IST ranking. We focused on finding interesting genes that were visible in multiple 
outlier detection methods. This was achieved by comparing the HUGO Gene No-
menclature Committee (HGNC) identification codes of the genes listed in the dif-
ferent methods with RStudio (version 1.2.5033, R package 3.5.2) using the 
merge() function. Figure 10 represents the found outlier genes as a VENN dia-
gram. This was further compared to outlier genes detected between MCC sub-
type specific outliers also compared with the merge() function,  visualized also in 
Figure 10.  
 
After obtaining a list of suitable and interesting genes, few selected genes were 
manually scrutinized in multiple online databases such as OMIM, DGIdb and IST 
online. Neurocan was chosen as our protein of interest, as it showed potential as 
a biomarker separating MCPyV+ and MCPyV- cases based on the SIBER, 
ranked gene list, GTI and hierarchical clustering of top 100 variance genes ar-
ranged for the parent project. It also seemed to be slightly misplaced, since it 
should be found mainly in central nervous system, and while MCC is considered 
neuroendocrine tumor, Neurocan over/under expression has not been reported 




the central nervous system have low Neurocan expression as displayed by Fig-




Figure 10. VENN diagrams of HGNC id distribution when comparing outlier gene detec-
tion methods and MCC subtypes by HGNC ids. SIBER = SIBER outlier gene detection 
method, deseq = ranked gene list, MCPyV+ vs MCPyV- cases, IST pos = IST-ranking, 
MCPyV+ cases, IST neg = IST-ranking, MCPyV- cases, GTI = Gene tissue indexing. 
 
A SIBER IST neg IST pos Ranked 
gene list 
GTI 
SIBER 19 0 0 6 19 
IST neg 0 112 0 112 112 
IST pos 0 0 44 44 44 
Ranked 
gene list 
19 112 44 4031 4031 
GTI 19 112 44 4031 13400 
 
 
B MCPyV+ MCPyV+ (2) MCPyV- 
MCPyV+ 4388 1963 1835 
MCPyV+ (2) 1963 3459 1521 
MCPyV- 1835 1521 4588 
Table 2. Number of genes in different gene outlier detection methods and their overlap. 


















When comparing the gene expression levels of MCPyV+ and MCPyV- tumors, 
Neurocan ranked 21st in the deseq2 based ranked gene list. GTI analysis sup-
ported the hypothesis of differential expression; however, this was statistically not 
significant. SIBER analysis provided much needed insight and visualized the 




Figure 13. SIBER analysis of Neurocan expression in MCPyV+ vs MCPyV- samples. 
 
The x-axis of the SIBER analysis represents the expression of NCAN in a given 
sample while the y-axis represents the number of samples. This gives us an over-
all expression profile of the samples, and when stratified with MCPyV status, we 





To confirm the bioinformatics findings of the differential expression, TMAs from 
the MCC sample series were immunohistochemically stained for Neurocan pro-
tein. 144 samples were stained and grouped into three categories based on the 
level of staining: low Neurocan expression (31 cases), intermediate Neurocan 
expression (60 cases) and high Neurocan expression (53 cases). Out of the 144 
samples 144 had survival data available (41 MCC related deaths) and 125 had 
MCPyV status identified. As described in Figure 14, in the low NCAN expression 
group 12 cases (54,5%) were MCPyV negative and 10 cases (45,5%) were 
MCPyV positive, in the intermediate group 17 cases (30,4%) were MCPyV neg-
ative and 39 cases (69,6%) were MCPyV positive and in the high expression 






This shows that there is an association in the cross tabulation, with high NCAN 
expression correlating with the MCPyV positive cases, where as low NCAN ex-
pression correlates with MCPyV negative cases. Pearsons chi-square test shows 
that this is a significant finding at a level of p=0.006. Taken together, these results 
confirm that there is a significant association between NCAN expression and 
MCPyV status, with low NCAN expression correlating with MCPyV negativity and 
vice versa. 
 




NCAN expression Low Count 12 10 
% 54,5% 45,5% 
Intermediate Count 17 39 
% 30,4% 69,6% 
High Count 8 39 
% 17,0% 83,0% 
Total Count 37 88 
% 29,6% 70,4% 
 
Figure 14. NCAN expression versus MCPyV status crosstabulation. Neurocan expres-




Next, we analyzed the effect of different NCAN expressions in patient survival. 
Kaplan-Meier method was used to analyze the differences between low, interme-
diate and high NCAN expression groups. As shown in Figure 15, there is a clear 




the two other groups (p-value = 0.044). When looking at overall patient survival, 
the story remains the same; low NCAN expression is associated with worse prog-
nosis (Figure 16). This is not surprising, as we have shown low NCAN expression 
associates to MCPyV negative MCC subtype, which has a worse prognosis than 
MCPyV positive subtype (Sihto, Kukko et al. 2009). Other clinical factors, patient 
age (p-value = 0.18), tumor size (p-value = 0.64), gender (p-value = 0.49), cancer 
stage (p-value = 0.63), location of the primary tumor (p-value = 0.25) and metas-
tasis at the time of diagnosis (p-value = 0.89), had no significant association with 
NCAN expression levels. 
 
It should be noted, that minimal data censoring was applied to the data, as the 
dataset that we had at our disposal is relatively small. Data censoring would in 
this case result in subgroups becoming too small to be statistically relevant. For 
example, if we censor all cases that lack MCPyV status and cases that have 
metastasis at the time of diagnosis (often censored as these patients have poor 
prognosis by default and could cause skewness in statistical analysis), or have 
this information missing, the amount of cases in MCPyV negative/high NCAN ex-
pression group would be limited to 4 cases. This hinders our ability to produce 
statistically reliable results. However, we understand that not censoring the data 
with certain parameters, such as metastasis at time of diagnosis, is going to affect 
the results, yet we decided that this is acceptable in the frame of this master’s 
thesis due to the limited sample size and time available.  
   
 





Figure 16. Overall patient survival. Kaplan-Meier survival analysis. 
 
 
Next, we analyzed whether NCAN is an independent variable causing the differ-
ence in patient prognosis. Cox proportional hazard model of different NCAN ex-
pression levels showed that low NCAN expression group had a 2.2 times higher 
hazard ratio (95% confidence interval: 1.03-4.7) compared to the reference group 
(high NCAN expression). However, this model was not statistically significant, 
possibly due to small data size, or high variance in survival in each group.  
 
When MCPyV status was added to the model, NCAN expression lost its signifi-
cance. This leads us to believe that NCAN related survival differences are indeed 
somehow connected to MCPyV (Figure 18). However, we can see the downside 
of working with a rare cancer clearly in these models. Achieving statistical signif-
icance is extremely difficult as the number of events (in this case, number of pa-
tients who died to MCC) is only 33. For a multivariate analysis like Cox propor-
tional hazards, this is a small amount. However, a significant result in a small 
dataset like these, is usually a promising sign and indicates that larger studies/da-










Figure 18. Cox proportional hazards regression model of NCAN and MCPyV status, 
MCC specific hazards. 
 
Moving on to a larger scale model, the small sample size started to provide sig-
nificant challenges. Only clinical variables that were prognostic factors in univari-
ate models (Kaplan-Meier) were added to the model. For example, age at the 
time of diagnosis was not a prognostic factor in our MCC sample series, and was 
thus not added to the model. To add the cancer stage to the analysis, we had to 
combine stage 3 and 4 cancers (stage 3 = local metastasis, stage 4 = distant 
metastasis/systemic disease), to achieve statistically relevant sample size for the 
groups (n=12 when combined). Other clinical variables (tumor size, patient gen-






Figure 19. Cox proportional hazards regression model, MCC specific hazards, multiple 
variables. F=female, M=male, loc=location of primary tumor, h=head and neck, l=limb 
and t=torso. 
 
It is clear that cancer stage is one of the hazardous factors in MCC specific sur-
vival. The other significantly hazardous factor in our model is the sex, with male 
gender having 4.31 (95%CI 1.465-12.7) times higher risk to die of MCC compared 
to females. Other variables of interest have lost their significance in the model. 
This hazard model needs to be expanded with additional data to increase its re-
liability, and biological variables such as cell proliferation marker Ki-67 should be 
added. While much of the data already exists in the dataset at our disposal, it is 
too fragmented to be used, and requires updating. However, the timeframe of this 
thesis is too short for this sort of maneuvers. This will be looked into in depth in 
the discussion section.  
 
When applying the models to overall survival, the story remains the same. How-
ever, the number of events and also the number of samples overall increased to 
acceptable sizes. Interestingly, the global p-value for the model remains statisti-
cally not significant in case of NCAN expression only and NCAN and MCPyV 
status combined. This implies that the variation in one of these variables is ex-
ceedingly high. This is probably due to NCAN expression levels high and inter-
mediate, which in the Kaplan-Meier survival analysis show similar prognosis for 
the patient, but in the eyes of a statistical analysis are represented the wrong way 
round as intermediate expression has marginally better prognosis. Indeed, if we 
combine these groups and focus on studying only low NCAN expression versus 
intermediate and high combined, we see that the model only containing NCAN 
expressions becomes statistically significant (Figure 21). However, the effect is 










Figure 21. Cox proportional hazards regression model, overall hazards, low NCAN ex-
pression versus combined intermediate and high NCAN expression. 
 
Once again, the NCAN expression loses its significance when other variables are 
added to the model. Interestingly the global p-value for NCAN and MCPyV status 
model remains non-significant even after combining the two groups as previously 
described (data not shown).  However, when including the rest of the clinical var-
iables, the model is highly significant (p-value < 0.01), and we can see that the 
only two significant variables contributing to the overall hazard (in this model) are 









Figure 23. Cox proportional hazards regression model, overall hazards, multiple varia-
bles. F=female, M=male, loc=location of primary tumor, h=head and neck, l=limb and 
t=torso. 
 
Overall, the Cox proportional hazards regression tells us a few things. Firstly, 
NCAN is not an independent variable when it comes to patient survival, and it is 
more likely functioning through MCPyV T-antigens or a common factor yet un-
known. Secondly, the dataset at our disposal needs to be further expanded and 
normal biological variables such as Ki-67, p53 and Rb should be incorporated to 





NCAN expression levels in MCC cell lines 
 
We first verified the MCPyV status of our cell lines with qPCR from DNA samples 
extracted from our cell lines prior to this project. The qPCR was performed with 
Roche Universal ProbeLibrary based assay. PTPRG was used as a reference 
gene and the MCPyV status was derived with LT3 (Large T-antigen transcript 
number 3). The list of primers used, and the protocol for the qPCR can be found 
in appendix 1 and 4, respectively. For all of the qPCR reactions, triplicate samples 
for each cell line were used. 
 
 
Figure 24. MCPyV status of MCC cell lines. A positive qPCR result equals MCPyV pos-
itivity. 
 
The results are in line with pre-existing data, and confirm the MCPyV status of 
our cell lines. Next, we analyzed the NCAN mRNA expression levels of our MCC 
cell lines with Bio-Rad SYBR Green based assay with GAPDH as a housekeep-
ing gene. The full protocol can be find in appendix 4. UISO and ME212 cell lines 
were excluded from further studies. UISO is a controversial MCC cell line as it 
does not resemble other MCCs, and its origin has been questioned. ME212 cell 
line has just been recently established and is still in a state of unstable growth. 
Thus the results might not be replicable, nor comparable to the other cell lines. 
 
 
Figure 25. NCAN mRNA expression in MCC cell lines. GAPDH used as reference gene. 
 
Figure 25 would imply that there are differences in NCAN mRNA expression lev-
els between different MCC cell lines. Furthermore, it would seem that MCPyV 




lines, as is the case in MCC patient samples. Indeed, when we analyzed the 
NCAN expression differences between MCPyV positive and MCPyV negative cell 
lines with Student’s t-test, we see that there is a statistically significant difference 
between these two groups (Table 5), when assuming that the variances between 





Levene's Test for Equality 
of Variances 
               
























Negative 3 3,86E-05 1,35E-05 7,78E-06 
 
Positive 6 2,47E-04 1,87E-04 7,64E-05 
 
9,937 0,016 
Table 3. Group statistics of NCAN expression qPCR and Levene's test for Equality of 
Variances in Student's t-test, MCC cell lines. Null hypothesis (variances between MCPyV 
positive and negative groups are equal) is rejected with a p-value of 0.016. 
 
To be noted, the sample size for both groups is very low (n=3 for MCPyV negative 
cell lines), and more samples would benefit the analysis greatly. Additional MCC 
cell lines are however, scarce and not available during the timeframe of this pro-
ject. 
 
Independent Samples Test 
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-2,721 5,103 0,041 -2,09E-04 7,67E-05 -4,05E-04 -1,27E-05 
Table 4. Student's t-test of MCC cell line NCAN expression levels. MCPyV status versus 
NCAN normalized expression levels. 
 
 
We next moved on to measuring the protein levels of both NCAN and MCPyV in 
the cell lines with western blotting as described previously. We first used antibod-
ies from Atlas Antibodies for NCAN and Santa Cruz for MCPyV T-antigen. The 
NCAN antibody seemed at first to be working; however, closer inspection re-




antibody, we were already aware that there are no commercial MCPyV T-antigen 
antibodies, that would be of good quality, not to mention interpretable. This 
proved to be the case later on when we got to silencing the genes with siRNAs, 
more of which later on. At the end, we chose to go further with the CM2B4 anti-
body and for the NCAN, we decided to try another antibody from Merck/Sigma 
Aldrich, that was ordered on accident and is specific for rat NCAN. However, as 
rat NCAN G1 and G3 domains share 92% homology (G2 domain 29%) with hu-
man NCAN, we decided to try the antibody with our samples. However, the re-




Figure 26. NCAN (Atlas Antibodies) western blot with MCC cell lines. Bands (cell lines) 
from left to right: MKL1, MS1, MKL2, MCC13, MCC14/2, MCC26, BroLi, PeTa, WaGa. 
 
 
Figure 27. CM2B4 (Santa Cruz) western blot with MCC cell lines, MCPyV status (+ or -) 
indicated in brackets. Bands (cell lines) from left to right: MKL1 (+), MS1 (+), MKL2 (+), 
MCC13 (-), MCC14/2 (-), MCC26 (-), BroLi (+), PeTa (+), WaGa (+). 
 
As is visible from Figures 26 and 27, the “protein levels” visualized with western 
blots do not correlate with the ones deduced from mRNA levels. Cytoskeletal 
actin was used as a housekeeping protein (data not shown) to verify that equal 
amounts of total protein lysates was applied from each cell line. Some possible 
reasons why the NCAN western blots did not work as hoped are further discussed 
later in this thesis, however, the western blots and thus the cell line protein levels 
of NCAN was deemed indecisive. For the MCPyV LT, we can clearly see that the 
specificity of the antibody is not optimal. While the specificity could have been 
improved, the timeframe of the thesis was too narrow for further optimization. 
While these results can not be used to tell the MCPyV status of the cell lines by 
themselves, we hoped that this level of specificity would have been enough for 





 siRNA knockdown of NCAN and MCPyV T-antigens 
 
Two MCPyV negative and two MCPyV positive MCC cell lines were picked for 
the siRNA studies: MCC13 (-), MCC26 (-), MKL1 (+) and WaGa (+). While there 
would have been cell lines with higher NCAN expression (based on qPCR results) 
and thus possibly more potential for the studies, we tried to incorporate cell lines 
that would have variation in their characteristics and would be easy to work with. 
MCC13 and MCC26 are both MCPyV negative cell lines and grow as an adherent 
monolayer, where as MKL1 and WaGa are MCPyV positive cell lines and grow 
as suspension cells; MKL1 in big spheroid like clusters and Waga as a single cell 
suspension. Working with all of the cell lines would have been too time consuming 
in the available timeframe, and we wanted to incorporate all of our cell lines to 
the siRNA studies in the future. This includes cell lines that are extremely slow to 
grow (BroLi) and cell lines that were not in a ready state at the time of these 
experiments (ME212).  
 
Prior to the actual siRNA studies, we optimized siRNA transfection protocol to our 
best extent. siGLO, a non-targeting siRNA tagged with GFP protein, was used in 
the optimization process. Two different transfection reagents were tested, 
Lipofectamine 2000 and Lipofectamine 3000, and Lipofectamine 2000 proved to 
be more suitable for these cell lines. To note, there are many other options for 
transfection reagents, however, these are the ones that we are familiar with and 
have provided reliable transfection results in our previous experiments. A total of 
7 different siRNA (siGLO) concentrations were tested (20,40,50,60,75,80 and 
100 nM) in two optimization rounds, and 75nM final concentration was decided 
to be the best compromise between inducing unspecific cell death and achieving 
proper transfection rates.. Appendix 5 shows a few examples of the transfection 
efficiency during the optimization steps.  
 
As described previously, the siRNA transfections lasted for 72 hours for the ly-
sates (both protein and RNA), where as the cell proliferation assay had three time 
points 0h, 48h, and 72h. Next we will go through these results individually.  
 
RNA and protein levels after siRNA knockdown 
 
We first looked at the RNA level changes resulting from the siRNA knockdown. 
For MKL1 the transfection seems to have worked nicely, with relative normalized 
mRNA levels reaching up to 35 fold numbers in the control siRNA group com-
pared to the others. These findings were also strongly significant in Student’s t-
test (p-value < 0.01). For Waga the story remains similar, except for T-antigen 
siRNA, which did not have an mRNA knockdown effect. For the sT and NCAN 
siRNAs, the Student’s t-test gives significant p-values of 0.002 and 0.004 respec-
tively for the NCAN expression levels, and 0.008 and 0.025 respectively for the 
LT3 expression levels. While the reduction in NCAN and LT3 expression levels 
is significant, we can observe that the transfection has worked better in the MKL1 
cell line. This was a bit surprising, as MKL1 was one of the harder cell lines to 
transfect with the siGLO siRNA. However, the sample size here is small, and 




study should be replicated to verify the results and to eliminate the possibility of 
false positive findings. 
 
Figure 28. NCAN and LT3 mRNA expression levels after siRNA treatments in MCPyV 
positive cell lines. ctrl = control siRNA, NCAN = NCAN targeting siRNA, sT = small T-
antigen targeting siRNA and TA = T-antigen targeting siRNA. Error bars are two times 
standard error of mean (2x SEM). 
 
For the MCPyV negative cell lines the story is completely different. Neither of the 
cell lines tested provided any significant results, and the results resemble mostly 
normal biological variance in cell growth. Neither of the cell lines showed any 
activity in the LT3 qPCR, which was expected. In the NCAN qPCR, we can see 
that something went wrong with the sT siRNA treated cell lines, as the relative 
normalized expression in the MCC26 cell line is over 50 times higher than in any 
of the other siRNA treatments. While primer dimer was not the issue in this case 
(as proved by melting curve analysis), the problem seems to be qPCR related. 
The problem seems to be related to the housekeeping gene, as the average 
GAPDH cycle threshold value in the sT samples is much higher than in other 
samples. However, as this is still under investigation, we excluded the sT siRNA 
in the MCC negative cell lines in the qPCR, and moved on with the rest. 
 
 
Figure 29. NCAN and LT3 mRNA expression levels after siRNA treatments in MCPyV 
negative cell lines. ctrl = control siRNA, NCAN = NCAN targeting siRNA, sT = small T-
antigen targeting siRNA and TA = T-antigen targeting siRNA. Error bars are two times 





After the exclusion of sT, we see that the knockdown has not provided us with 
the expected results (Figure 30). For both of the cell lines, the non-targeting con-
trol siRNA has lower values than the targeting siRNAs. None of these findings 
were statistically significant, (Student’s t-test, p-value > 0.5 for both cell lines and 
all of the targeting siRNAs.) which leads us to believe that this is a matter of 
biological variance in cell growth instead of a siRNA related effect. The mRNA 
levels of NCAN in both of the cell lines are relatively low (as visualized by Figure 
25), so it is possible that neither of these cell lines actually have significant 
amounts of mRNA in production. These experiments should be repeated to avoid 
false negative results, however, as they are, they would support our hypothesis 
of a connection between MCPyV and NCAN. 
 
 
Figure 30. qPCR results in MCPyV negative cell lines after censoring sT siRNA treated 
groups. Error bars two times standard error of mean. 
 
At protein level, the findings are rather disappointing. As previously described 
neither of the NCAN antibodies showed specific binding for the whole NCAN pro-
tein in western blots. However, as NCAN protein is highly modifiable, and like 
Zhang et al. showed even the cleaved versions of CSPGs can have a major effect 
in tumor infiltration (Zhang, Kelly et al. 1998), we proceeded to study the protein 
levels of siRNA knockdown models with both available antibodies. For the 
CM2B4 (MCPyV T-antigen) antibody, we tested only the MCPyV positive cell 
lines, as the MCPyV negative cell lines did not show any expression at the mRNA 
level, as expected. 
 
The CM2B4 antibody did not reveal any changes in the cell lines after the siRNA 
treatments. Both MKL1 and WaGa cell lines had bands visible in similar sizes, 
but no differences could be visually detected (Figure 31). The results are similar 
for both of the NCAN antibodies, with a small exception in the rat specific NCAN 
antibody (Sigma Ald.), which showed decreased NCAN expression in the T-anti-
gen siRNA treated WaGa cell line (Figure 32). However, this band was located 
at a size of roughly 70kDa, which does not represent any of the known fragment 
sizes of even cleaved NCAN protein. It is likely, that these bands are unspecific 
binding to IgG heavy chains, or some other high protein binding affinity antigen. 
The human specific NCAN antibody (Atlas Ab.) did not reveal any differences in 







Figure 32. NCAN (Sigma Ald.) antibody western blot. WaGa (left) and MKL1 (right) cell 
lines, with (from left to right) control siRNA, T-antigen siRNA, sT-antigen siRNA and 
NCAN siRNA treatment. 
 
 
Figure 33. NCAN (Atlas Ab.) antibody western blot. WaGa (left, 4 lanes) and MKL1 (right, 
4 lanes) cell lines, with (from left to right) control siRNA, T-antigen siRNA, sT-antigen 
siRNA and NCAN siRNA treatment. 
 
The results were highly similar for the MCPyV negative cell lines. Neither of the 
tested antibodies revealed any differences between the treatments (Figures 34 
and 35). With the human NCAN antibody, the bands took a while longer exposure 
to be visible when compared to the MCPyV positive cell lines, which could indi-
cate a difference in the protein levels between the MCPyV subgroups. However, 
the bands were visible and same size with the MCPyV positive cell lines, which 
supports the hypothesis that this is unspecific binding. While the protein expres-
sion results were underwhelming, there are a few reasons why this happened, 
and these will be covered in the discussion section.  
 
 
Figure 34. Figure 35. NCAN (Sigma Ald.) antibody western blot. MCC13 (left) and 
MCC26 (right) cell lines, with (from left to right) control siRNA, T-antigen siRNA, sT-
antigen siRNA and NCAN siRNA treatment. 
 
Figure 31. CM2B4 (MCPyV) antibody western blot with WaGa (left) and MKL1 (right) cell 
lines. The bands from left to right: control siRNA, T-antigen siRNA, sT-antigen siRNA and 






Figure 36. NCAN (Atlas Ab.) antibody western blot. MCC13 (left, 4 lanes) and MCC26 
(right, 4 lanes) cell lines, with (from left to right) control siRNA, T-antigen siRNA, sT-
antigen siRNA and NCAN siRNA treatment. 
 
 
Cell proliferation after siRNA knockdown 
 
 
For the cell proliferation assays, we used CellTiter-GLO kit (Promega) as de-
scribed previously. For MKL1 we can see a small growth difference between the 
control siRNA treated and sT and NCAN siRNA treated goups at the 48h time 
point. At the 72h time point, all of the siRNA treated groups show a small growth 
reduction (average 8%) compared to the control group. For Waga, only sT siRNA 
treated group shows any reduction in growth, with 6,2% difference at 48h time 
point and 18% growth reduction at the 72h time point. These differences are ad-
mittedly small, and only the sT siRNA treatment of WaGa shows statistical signif-
icance (Student’s t-test, p-value = 0.01). These studies were repeated twice with 
similar results, indicating the validity of this test. Compared to the mRNA level 
reduction in qPCR, these findings are underwhelming. Figure 37 visualizes these 
findings. 
 
These findings are also surprising, considering that the siRNAs were designed 
by Kwun et al., who managed to present significant reduction in the MCPyVs viral 
replication and T-antigen production abilities after siRNA transfection with a sim-
ilar setup to ours (Kwun, Guastafierro et al. 2009). This should lead to a significant 
reduction of cell growth in MCPyV positive cell lines, provided that MCPyV T-
antigens have been proven to be major contributors in MCPyV dependent carcin-
ogenesis.  
 
The cell proliferation changes in MCPyV negative cell lines following the siRNA 
treatments could not be tested during the timeframe of this thesis. While the ex-
periments were already scheduled, the recent outbreak of the COVID-19 pan-
demic caused significant changes in the planned experiments. However, prelim-
inary data from the MCPyV negative MCC 26 cell line is available, as this was 
used in optimizing the workflow of the CellTiter-GLO assay. The cell line showed 
no significant changes (if any) in its growth following the siRNA treatments at 48h 
time point (Figure 38). This was expected, and could potentially be used (if ex-



































ctrl TA sT NCAN
Figure 37. Cell proliferation assay results. x-axis = 0h, 48h or 72h time point, y-axis = 
Luminescence counts/0,5s (Hidex Sense). . ctrl = control siRNA, NCAN = NCAN targeting 








It is quite obvious from Figure 10 and Table 2, that the bioinformatics would have 
benefitted from additional gene outlier detection methods to allow for identifica-
tion of common outliers across various methods. At the time of NCAN identifica-
tion, no additional outlier gene detection methods were available unfortunately. 
This method of narrowing down the findings by inclusion of different outlier gene 
detection methods proved to be useful however, and the amount of data still re-
maining is vast. By inclusion of methods such as COPA (cancer outlier profile 
analysis) and outlier sum (OS) statistics could potentially reduce the number of 
false positive findings by “inclusion in all datasets” type of approach. As Mpindi 
et al. showed in their article, GTI, COPA and OS only partially overlap in outlier 
genes detected (Mpindi, Sara et al. 2011), which they deduced means that some 
or all of them must include either false positive or negative findings.  
 
However, these methods have been commonly used in studies such as the par-
ent project of this thesis. Thus, the research groups idea was to use novel meth-
ods to produce novel findings. This has been shown to be an effective strategy 
in the past by the research group members. For example, discovery of Anagrelide 
as a potential therapeutic drug for gastrointestinal stromal tumors was based on 
identification of PDE3A as an outlier gene by similar methods as ours (Pulkka, 
Gebreyohannes et al. 2019). And while the findings represented in this thesis 
might not be leading to therapeutic drug development, they still have potential as 
novel biomarker for MCC and could be used in the future to expand the 
knowledge of T-antigen functionality in MCC.  
 
Figure 38. siRNA optimization for CellTiter-GLO with MCC26 cell line. 48h time point, x-




The immunohistochemistry provided us with a clear association between pa-
tients’ prognosis and NCAN protein expression levels. This is in line with other 
studies regarding CSPGs and cancer (Zhang, Kelly et al. 1998). Our results were 
achievable with an untrained person (namely the author) analyzing the TMA 
slides while being blinded of the patients’ clinical and biological data. As such, 
this could be easily incorporated into the clinical setting, and used by doctors 
when evaluating the treatments and prognosis of the patients. Complementing 
the IHC staining with machine learning algorithms could also potentially minimize 
the human errors, and produce more reliable data. 
 
Certain aspects of the IHC staining were not described in this thesis. While NCAN 
is an extracellular protein and mainly secreted out of the cells, we noted that some 
samples included intracellular staining of the NCAN protein. This was visible 
throughout the different expression levels. This was studied briefly, but it had no 
statistical significance in patient prognosis, nor did it have any correlation with 
other clinical data available. And while the data gathered would suggest that MCC 
cell lines could technically produce NCAN protein, the source of the NCAN protein 
in patient samples remains unverified.  
 
A clear downside of this study has been the small sample size. While the number 
of patients is extremely high considering the rarity of the cancer and the popula-
tion it is derived from, it is still hard to produce reliable data from it. Firstly, since 
the patient samples have been collected between 1983 and 2012, a lot of varia-
tion is introduced just by time and age of the samples themselves. While it was 
not mentioned previously, we analyzed and discovered that the collection time of 
these samples did not correlate with the NCAN expression levels. When studying 
protein levels from FFPE samples, this is not always the case. Another problem 
is the scarcity of the data. For example, standard biological markers, such as cell 
proliferation marker Ki-67, have been studied from only a proportion of the sam-
ples available. This translates into the fact, that only 86 out of 144 samples with 
NCAN staining data available have also Ki-67 data available. Even obvious cases 
like RB and p53 had to be left out because of the low number of cases having 
both of the expression levels available. In the future, the dataset needs to be 
updated, to be able to analyze associations between these known biological 
markers with novel markers, such as NCAN. 
 
The protein expression studies otherwise were a complete failure. Both the T-
antigen and NCAN expression levels were uninterpretable from the western blots, 
the primary method for protein level expression studies planned for this project. 
While the T-antigen antibody was previously known to be difficult to interpret, 
other studies have successfully used it to interpret MCPyV T-antigen expression 
levels (Dye, Welcker et al. 2019). Thus, it surprised us how messy the western 
blots truly were. In an unpublished study, we tested these unspecific bands of the 
western blotting with peptide sequencing and found that the CM2B4 antibody has 
a high affinity towards different PP2A subunits, which is not surprising consider-
ing the interactions of T-antigens with PP2A previously described. A short litera-
ture review made it clear, that the biggest and most known research groups stud-
ying MCC are producing their antibodies by themselves. While there are clear 
instructions available for this sort of antibody production, the pipeline should have 




outside of the actual thesis. This is something to look forward to in the future, as 
better methods of T-antigen protein level analysis are clearly required. 
 
When it comes to the protein levels of NCAN in MCC samples, a clear mistake 
was made in the designing phase of the study. Since NCAN is mainly an extra-
cellular protein, and thus mainly excreted out of the cells, it would have made 
more sense to study the supernatants left from the cells instead of the cells them-
selves. Methods such as ELISA could have easily been incorporated into the 
study, had this occurred to us at an earlier phase. However, the COVID-19 pan-
demic prevented us from doing such measures (not to speak of preventing us 
from replicating our results). With the limited timeframe of a masters’ thesis, this 
is the best we could come up with. However, the secreted NCAN levels will be 
studied in the future, as the situation with COVID-19 gets easier. 
 
For the qPCR, everything seemed to work as intended. The primers were tested 
beforehand (data not shown), and they produced a product of the predicted size 
in standard PCR. While originally designed for Roche Universal ProbeLibrary 
qPCR assay, the primers were suited for other qPCR assays and even surpassed 
the Roches method. Biological replicates were not introduced to the experiments, 
solely due to time constraints. This does have an impact on the reliability of the 
results and will be attended to afterwards. 
 
While we were happy with the transfection efficacy after the optimization periods, 
it is to be said that much more could have been done here. First of all, the results 
from T-antigen knockdown are a mixed bag. The mRNA levels of all of MKL1 cell 
line with all of the different siRNA treatments are significantly lower than those of 
the control groups. This was also the case in NCAN and sT siRNA treated WaGa 
cells, where as neither of the MCPyV negative cell lines responded to either treat-
ment. This would indicate a successful transfection. While this could not be veri-
fied on the protein level, due to improper detection methods used and poor anti-
bodies, the initial response was positive. 
 
However, in case of proper siRNA transfection efficiency and T-antigen siRNA 
targeting, we would assume to reach significant growth reduction of the MCPyV 
positive cell lines. This has been the case for a number of studies including those 
of Houben et al. and Shuda et al. (Houben, Shuda et al. 2010, Shuda, Kwun et 
al. 2011). However, many have used shRNAs and viral transfection instead of 
siRNA combined with transfection reagent such as lipofectamine. This and the 
fact that sT siRNA treated WaGa cell line and all of the treated MKL1 cell lines 
showed slight growth reduction (sT WaGa being the only statistically significant 
one) would indicate that the transfection efficiency was our downfall in this study. 
There are a vast amount of different transfection reagents available, as well as 
completely different silencing methods (like the before mentioned shRNAs and 
CRISPR technologies to name a few), so achieving better transfection efficien-
cies and thus better gene knockdown effects is only a matter of optimization.  
 
However, the slight growth reduction that we achieved does raise more ques-
tions, which is often a positive outcome of an experiment. For example, while the 
transfection worked based on the mRNA levels, why did it not transfer into the 




the MCPyV positive cells growing in suspension, we could not change the growth 
media of the cells prior to administration of the siRNAs. There is a possibility that 
the cells have secreted a sufficient amount of T-antigens and NCAN into the 
growth medium, delaying the impact of a siRNA transfection. This could be indi-
cated by the late response to the T-antigen siRNA treatment in MKL1 cells, as 
seen in Figure 37. However, in the case of T-antigen this has not been reported, 
and it seems unlikely, as T-antigens are used mainly intracellularly. Another op-
tion is that the amount of NCAN and T-antigen produced are so low, that the 
qPCR results give falsely high expression level changes as a result. As men-
tioned previously, other groups have successfully transfected MCC cell lines with 
T-antigen targeting siRNAs and shown significant growth reduction, so this is un-
likely. 
 
The role of NCAN in MCC remains elusive. The patient data shows that low 
NCAN expression associates to worse patient prognosis. This combined with the 
findings of Zhang et al. and Silver et al. supports a hypothesis (Silver et al.) that 
NCAN (like other CSPGs) would have an inhibitory role in tumor invasiveness 
more than an invasion promoting effect (Zhang, Kelly et al. 1998, Silver, D. J., 
Siebzehnrubl et al. 2013, Silver, D. J., Silver 2014). However, looking at the qPCR 
data, we see that targeting NCAN with siRNAs decreases the LT3 expression 
and vice versa, suggesting a possible signaling loop between these two proteins. 
This needs to be further investigated, as it could provide important insight into the 





Overall, the primary results of this thesis were partially satisfied. We identified a 
novel biomarker specific for the MCPyV positive subtype of Merkel cell carcinoma 
based on bioinformatics data, and proved that the specificity carries over to our 
patient data as well as MCC cell lines in our collection. Low NCAN expression 
was significantly associated to poor patient prognosis in immunohistochemistry, 
however, Cox proportional hazards model revealed that NCAN is not an inde-
pendent variable in patient survival. Other clinical factors, such as patient age 
and gender, did not associate significantly with NCAN expression levels.  
 
Low NCAN expression is associated with MCPyV negative subtype in MCC cell 
lines at mRNA level. The protein levels remain inconclusive, due to mistakes in 
experimental design and poor antibody specificity in western blotting. This result 
further indicates that there is a significant difference in NCAN expression in dif-
ferent MCC subtypes. 
 
siRNA knockdown of NCAN reduced the expression of both NCAN and LT3 
(MCPyV T-antigen) significantly in MCPyV positive cell lines at mRNA levels. 
Similarly, the knockdown of both small T-antigen and the large (complete) T-an-
tigen reduced the expression of NCAN in MCPyV positive cell lines in qPCR. 
Complementary, the MCPyV negative cell lines saw no significant changes, with 
any siRNA treatments when compared to the control treatment. This suggests 






All of the siRNA treatments on MKL1 cell line had a slight but not significant re-
duction in their growth. Only sT siRNA treated WaGa cells showed any response 
to the treatment, however, this was statistically significant finding. MCPyV nega-
tive cell lines were not properly tested due to time shortage caused by the recent 
outbreak of COVID-19 pandemic. Other functional studies that had been planned, 
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Appendix 1. Primers used in the project 
Pri-
mers 









LT3 NA NA 
for  
rev  
NCAN ENSG00000130287.13 84 
for  
rev  
PTPRG ENSG00000144724 NA 
for  
rev  
     
Pri-
mers 
Sequence 5' - 3' TM GC% Position 
GAPDH 
TCAAGATCATCAGCAATGCC 58 45 
6537204-
6537315 





NA NA NA TTTTGCCTTATA-
GACTTTTCCATATCT 
NCAN 
GGCAGCTTTTGTGAGAAAGAC 59 48 3331 - 3351 
GTGGGCAAAATAGCGGTAAC 59 50 3395 - 3414 
PTPRG 
TATGGGAGTGTGGGATGGTT 







Appendix 2. Immunohistochemistry protocols 
 
NCAN (Atlas AB: HPA036814)    IHC 
Antibody produced in Rabbit    Salmikangas 2019 
 
 
1. Xyl-, descending EtOH-series, H2O wash 
2. 30 min H2O2 (200ml H2O + 5ml H2O2 35%) 
3. 2 x H2O wash 
4. HIER with EnVision™ Flex Target Retrieval solution Low pH buffer, 
15min 95C, let cool for 2h 
5. 2 x wash with TBS 
6. Dilute NCAN 1:200 with Draco antibody diluent 
- 150ul / slide + overnight incubation +4C 
7. 2x TBS wash 
8. WellMed Orion detection system, Rabbit HRP 150uL/slide, 60min RT’ 
9. 2x TBS wash 
10. Dilute DAB (ImmPact DAB) 1mL buffer + 1 drop of DAB, 100uL/slide, 
5min RT’ 
11. 2x TBS wash 
12. H2O wash 
13. Hematoxylin1 min + 10 min under running water 





Appendix 3. Western blot protocols 
 
NCAN (Atlas Antibodies: HPA036814)    Western blot 
Antibody produced in Rabbit    Salmikangas 2020 
 
 
1. Pipette 5µg of each pretreated and denatured protein lysate and protein 
ladder on SDS-PAGE gel 
2. Run the gel with 100V constant for roughly 1,5 hours, or until the lead-
ing buffer nears the end of the gel 
3. Remove the gel from the holder and stack it in between the Trans-Blot 
Turbo Transfer Pack. The bottom and top portions are labeled, and the 
gel comes in between them. 
4. Transfer the proteins to the PVDF membrane included in the transfer 
pack with Bio-Rad Trans-Blot Turbo. Use the pre-installed protocol 
Mixed molecular weights, 1,3A, 7min. 
5. Block the membrane with 5% skimmed milk in WB Wash Buffer 
6. Wash the membrane three times with WB Wash Buffer (Optional), 5 
minutes on a shaker 
7. Dilute NCAN primary antibody 1:1000 in 1% skimmed milk in WB 
Wash Buffer 
a. Incubate the membrane in the primary antibody overnight in 
+4°C 
8. Wash the membrane three times with WB Wash Buffer, 5 minutes on a 
shaker 
9. Dilute mouse-anti-Rabbit secondary antibody 1:10 000 in 1% 
skimmed milk in WB Wash Buffer 
a. Incubate the membrane in the secondary antibody for 1h at room 
temperature 
10. Wash the membrane three times with WB Wash Buffer, 5 minutes on a 
shaker 
11. Mix equal volumes of SuperSignal West Pico PLUS reagents, and incu-
bate the membrane for 5 minutes at room temperature 
12. Visualize the membrane with x-ray film exposure. 
 





NCAN (Merck/Sigma: N0913)  Western blot 
Antibody produced in Mouse    Salmikangas 2020 
 
 
1. Pipette 5µg of each pretreated and denatured protein lysate and protein 
ladder on SDS-PAGE gel 
2. Run the gel with 100V constant for roughly 1,5 hours, or until the lead-
ing buffer nears the end of the gel 
3. Remove the gel from the holder and stack it in between the Trans-Blot 
Turbo Transfer Pack. The bottom and top portions are labeled, and the 
gel comes in between them. 
4. Transfer the proteins to the PVDF membrane included in the transfer 
pack with Bio-Rad Trans-Blot Turbo. Use the pre-installed protocol 
Mixed molecular weights, 1,3A, 7min. 
5. Block the membrane with 5% skimmed milk in WB Wash Buffer 
6. Wash the membrane three times with WB Wash Buffer (Optional), 5 
minutes on a shaker 
7. Dilute NCAN primary antibody 1:1000 in 1% skimmed milk in WB 
Wash Buffer 
a. Incubate the membrane in the primary antibody overnight in 
+4°C 
8. Wash the membrane three times with WB Wash Buffer, 5 minutes on a 
shaker 
9. Dilute rabbit-anti-Mouse secondary antibody 1:10 000 in 1% 
skimmed milk in WB Wash Buffer 
a. Incubate the membrane in the secondary antibody for 1h at room 
temperature 
10. Wash the membrane three times with WB Wash Buffer, 5 minutes on a 
shaker 
11. Mix equal volumes of SuperSignal West Pico PLUS reagents, and incu-
bate the membrane for 5 minutes at room temperature 
12. Visualize the membrane with x-ray film exposure. 
 





Actin (Bethyl labs: A300-491A) Western blot 
Antibody produced in Rabbit    Salmikangas 2020 
 
 
1. Pipette 5µg of each pretreated and denatured protein lysate and protein 
ladder on SDS-PAGE gel 
2. Run the gel with 100V constant for roughly 1,5 hours, or until the lead-
ing buffer nears the end of the gel 
3. Remove the gel from the holder and stack it in between the Trans-Blot 
Turbo Transfer Pack. The bottom and top portions are labeled, and the 
gel comes in between them. 
4. Transfer the proteins to the PVDF membrane included in the transfer 
pack with Bio-Rad Trans-Blot Turbo. Use the pre-installed protocol 
Mixed molecular weights, 1,3A, 7min. 
5. Block the membrane with 5% skimmed milk in WB Wash Buffer 
6. Wash the membrane three times with WB Wash Buffer (Optional), 5 
minutes on a shaker 
7. Dilute Actin primary antibody 1:100 000 in 1% skimmed milk in WB 
Wash Buffer 
a. Incubate the membrane in the primary antibody overnight in 
+4°C 
8. Wash the membrane three times with WB Wash Buffer, 5 minutes on a 
shaker 
9. Dilute mouse-anti-Rabbit secondary antibody 1:10 000 in 1% 
skimmed milk in WB Wash Buffer 
a. Incubate the membrane in the secondary antibody for 1h at room 
temperature 
10. Wash the membrane three times with WB Wash Buffer, 5 minutes on a 
shaker 
11. Mix equal volumes of SuperSignal West Pico PLUS reagents, and incu-
bate the membrane for 5 minutes at room temperature 
12. Visualize the membrane with x-ray film exposure. 
 





CM2B4 (Santa Cruz, sc-136172)    Western blot 
Antibody produced in Rabbit    Salmikangas 2019 
 
 
1. Pipette 5µg of each pretreated and denatured protein lysate and protein 
ladder on SDS-PAGE gel 
2. Run the gel with 100V constant for roughly 1,5 hours, or until the lead-
ing buffer nears the end of the gel 
3. Remove the gel from the holder and stack it in between the Trans-Blot 
Turbo Transfer Pack. The bottom and top portions are labeled, and the 
gel comes in between them. 
4. Transfer the proteins to the PVDF membrane included in the transfer 
pack with Bio-Rad Trans-Blot Turbo. Use the pre-installed protocol 
Mixed molecular weights, 1,3A, 7min. 
5. Block the membrane with 5% skimmed milk in WB Wash Buffer 
6. Wash the membrane three times with WB Wash Buffer (Optional), 5 
minutes on a shaker 
7. Dilute CM2B4 primary antibody 1:1000 in 1% skimmed milk in WB 
Wash Buffer 
a. Incubate the membrane in the primary antibody overnight in 
+4°C 
8. Wash the membrane three times with WB Wash Buffer, 5 minutes on a 
shaker 
9. Dilute mouse-anti-Rabbit secondary antibody 1:10 000 in 1% 
skimmed milk in WB Wash Buffer 
a. Incubate the membrane in the secondary antibody for 1h at room 
temperature 
10. Wash the membrane three times with WB Wash Buffer, 5 minutes on a 
shaker 
11. Mix equal volumes of SuperSignal West Pico PLUS reagents, and incu-
bate the membrane for 5 minutes at room temperature 
12. Visualize the membrane with x-ray film exposure. 
 





Appendix 4. qPCR protocols 
 
Roche Universal ProbeLibrary qPCR 
 





Reverse Primer 10uM 0.5 
UPL Probe# 10uM 0.2 
UPL MasterMiX 5 
DNA template 100ng 
Water ad 10µl 
 
 
Thermal cycling protocol: 
 
Step 1. Initial DNA denaturation/polymerase activation 
- 95°C, 10min 
Step 2. DNA denaturation 
- 95°C, 10s 
Step 3. Annealing 
- 60°C, 30s 
Step 4. Elongation 
- 72°C, 1s 
- Plate read/Acquisition 
 
Repeat to Step 2 44 times (total 45 cycles) 
 
Step 5. Melting curve 
- 65-95°C 
- 0,5°C increment 
 
Step 6. Cooling 






SsoAdvanced Universal SYBR Green Supermix  
 
Reaction setup (1 qPCR reaction): 
 
 ul 
Forward Primer 10uM 0.5 
Reverse Primer 10uM 0.5 
SYBR GREEN MasterMiX 5 
DNA template 100ng 
Water ad 10µl 
 
 
Thermal cycling protocol: 
 
Step 1. Initial DNA denaturation/polymerase activation 
- 95°C, 30s 
Step 2. DNA denaturation 
- 95°C, 15s 
Step 3. Annealing and elongation 
- 60°C, 30s 
- Plate read/Acquisition 
 
Repeat to Step 2 44 times (total 45 cycles) 
 
Step 4. Melting curve 
- 65-95°C 
- 0,5°C increment 
 
Step 5. Cooling 









Appendix 5. Example images of siRNA transfection optimization 
 
MCC13 24-well plate, 1ul Lipofectamine 2000, 50nM siGLO, 1/100s exposure 





WaGa 24-well plate, 1ul Lipofectamine 2000, 50nM siGLO, 1/100s exposure 








MCC13 24-well plate, 2ul Lipofectamine 2000, 50nM siGLO, 1/100s exposure 





WaGa 24-well plate, 2ul Lipofectamine 2000, 50nM siGLO, 1/100s exposure 
AUTO settings ISO 400 
 
 
